SCHEMBL21687537

SCHEMBL21687537

N#Cc1ccc2c(c1)c1ccccc1n2-c1cccc(-c2c([Si](c3ccccc3)(c3ccccc3)c3ccccc3)ccc(C#N)c2C#N)c1

nearest known ligand 0.34

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 4/20 0.34
LMNA P02545 4/20 0.34
SMN1; SMN2 Q16637 2/20 0.34
MAPK1 P28482 2/20 0.34
HPGD P15428 1/20 0.34
HIF1A Q16665 1/20 0.33
KDM4E B2RXH2 2/20 0.32
ATM Q13315 1/20 0.32
L3MBTL1 Q9Y468 1/20 0.32
ADORA2A P29274 1/20 0.31
ADORA1 P30542 1/20 0.31
TSHR P16473 3/20 0.31
CYP1A2 P05177 4/20 0.30
CYP3A4 P08684 3/20 0.30
MEN1 O00255 3/20 0.30
KMT2A Q03164 3/20 0.30
CYP2C19 P33261 2/20 0.30
CLK4 Q9HAZ1 2/20 0.30
CYP2D6 P10635 2/20 0.30
HSD17B10 Q99714 2/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21687753 0.94 SMN1; SMN2 (0.38) ALDH1A1LMNASMN1; SMN2MAPK1HPGD
SCHEMBL21687510 0.92 LMNA (0.34) ALDH1A1LMNASMN1; SMN2MAPK1HPGD
SCHEMBL21687741 0.91 KDM4E (0.33) ALDH1A1LMNASMN1; SMN2MAPK1HPGD
SCHEMBL21687689 0.89 KDM4E (0.34) ALDH1A1LMNASMN1; SMN2MAPK1HPGD
SCHEMBL21687485 0.87 KDM4E (0.34) ALDH1A1LMNASMN1; SMN2MAPK1HPGD
SCHEMBL21687496 0.87 ALDH1A1 (0.36) ALDH1A1LMNASMN1; SMN2MAPK1HPGD
SCHEMBL21687850 0.86 KDM4E (0.32) ALDH1A1LMNASMN1; SMN2MAPK1HPGD
SCHEMBL21688047 0.86 KDM4E (0.33) ALDH1A1LMNASMN1; SMN2MAPK1HPGD
SCHEMBL21687487 0.86 LMNA (0.35) ALDH1A1LMNASMN1; SMN2MAPK1HPGD
SCHEMBL21687755 0.86 SMN1; SMN2 (0.38) ALDH1A1LMNASMN1; SMN2MAPK1HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11201300-B2 Condensed cyclic compound and organic light-emitting device including condensed cyclic compound SAMSUNG ELECTRONICS CO., LTD. (KR) 2021-12-14 US disclosed
US-20200044168-A1 CONDENSED CYCLIC COMPOUND AND ORGANIC LIGHT-EMITTING DEVICE INCLUDING CONDENSED CYCLIC COMPOUND SAMSUNG ELECTRONICS CO., LTD. (KR) 2020-02-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200044168-A1 CONDENSED CYCLIC COMPOUND AND ORGANIC LIGHT-EMITTING DEVICE INCLUDING CONDENSED CYCLIC COMPOUND CRY1, CCNL2, CCNE2 ALDH1A1 616/4885LMNA 1582/4885SMN1; SMN2 4039/4885
US-11201300-B2 Condensed cyclic compound and organic light-emitting device including condensed cyclic compound CRY1, CCNL2, CCNE2 ALDH1A1 616/4885LMNA 1582/4885SMN1; SMN2 4039/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.